HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study

Altice, 2010, Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs., Lancet, 376, 59, 10.1016/S0140-6736(10)60829-X

Masur, 1981, An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction., N Engl J Med, 305, 1431, 10.1056/NEJM198112103052402

Stancliff, 2004, Buprenorphine and the treatment of opioid addiction., The PRN Notebook, 9, 28

Fiellin, 2002, Clinical practice. Office-based treatment of opioid-dependent patients., N Engl J Med, 347, 817, 10.1056/NEJMcp013579

Kreek, 2002, History and current status of opioid maintenance treatments: blending conference session., J Subst Abuse Treat, 23, 93, 10.1016/S0740-5472(02)00259-3

2003, Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003., MMWR Morb Mortal Wkly Rep, 52, 329

2003, HIV diagnoses among injection-drug users in states with HIV Surveillance--25 states, 1994-2000., MMWR Morb Mortal Wkly Rep, 52, 634

Kozal, 2005, HIV drug resistance and HIV transmission risk behaviors among active injection drug users., J Acquir Immune Defic Syndr, 40, 106, 10.1097/01.qai.0000159666.95455.d2

Fisher, 2004, Clinician-initiated HIV risk reduction intervention for HIV-positive persons: formative research, acceptability, and fidelity of the Options Project., J Acquir Immune Defic Syndr, 37, S78, 10.1097/01.qai.0000140605.51640.5c

De Cock, 2009, Preventing HIV transmission with antiretrovirals., Bull World Health Organ, 87, 488, 10.2471/BLT.09.067330

Granich, 2009, Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model., Lancet, 373, 48, 10.1016/S0140-6736(08)61697-9

Tuldra, 2002, Interventions to improve adherence to antiretroviral therapy., J Acquir Immune Defic Syndr, 31, S154, 10.1097/00126334-200212153-00014

Mattick, 2002, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence., Cochrane Database Syst Rev, 4, CD002207

Yoast, 2001, Report of the Council on Scientific Affairs: methadone maintenance and needle-exchange programs to reduce the medical and public health consequences of drug abuse., J Addict Dis, 20, 15, 10.1300/J069v20n02_03

Fiellin, 2002, Treatment of heroin dependence with buprenorphine in primary care., Am J Drug Alcohol Abuse, 28, 231, 10.1081/ADA-120002972

Johnson, 2000, A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence., N Engl J Med, 343, 1290, 10.1056/NEJM200011023431802

Johnson, 1995, A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence., Drug Alcohol Depend, 40, 17, 10.1016/0376-8716(95)01186-2

Fiellin, 2001, Office-based treatment for opioid dependence: reaching new patient populations., Am J Psychiatry, 158, 1200, 10.1176/appi.ajp.158.8.1200

Kosten, 1991, Treatment of heroin addicts using buprenorphine., Am J Drug Alcohol Abuse, 17, 119, 10.3109/00952999108992815

Fiellin, 2004, Consensus statement on office-based treatment of opioid dependence using buprenorphine., J Subst Abuse Treat, 27, 153, 10.1016/j.jsat.2004.06.005

Altice, 2006, The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention., Clin Infect Dis, 43, S178, 10.1086/508181

Melo, 2006, Utilization of HIV/AIDS treatment services: comparing injecting drug users and other clients., Cad Saude Publica, 22, 803, 10.1590/S0102-311X2006000400019

Bruce, 2007, Clinical care of the HIV-infected drug user., Infect Dis Clin North Am, 21, 149, 10.1016/j.idc.2007.03.009

Johnson, 2000, A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence., N Engl J Med, 343, 1290, 10.1056/NEJM200011023431802

Lucas, 2010, Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial., Ann Intern Med, 152, 704, 10.7326/0003-4819-152-11-201006010-00003

Cheever, 2011, A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care., J Acquir Immune Defic Syndr, 56, S3, 10.1097/QAI.0b013e318209740f

McLellan, 1980, An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index., J Nerv Ment Dis, 168, 26, 10.1097/00005053-198001000-00006

McLellan, 1992, The fifth edition of the addiction severity index., J Subst Abuse Treat, 9, 199, 10.1016/0740-5472(92)90062-S

Wu, 1997, Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS., Qual Life Res, 6, 531, 10.1023/A:1018460132567

Springer, 2009, Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy., AIDS Care, 21, 976, 10.1080/09540120802657555

Leonhard, 2000, The Addiction Severity Index: a field study of internal consistency and validity., J Subst Abuse Treat, 18, 129, 10.1016/S0740-5472(99)00025-2

2010, Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies., Clin Infect Dis, 50, 1387, 10.1086/652283

2010, High, CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study., Lancet, 376, 340, 10.1016/S0140-6736(10)60932-4

Tien, 2010, Inflammation and mortality in HIV-infected adults: analysis of the FRAM Study Cohort., J Acquir Immune Defic Syndr, 55, 316, 10.1097/QAI.0b013e3181e66216

2006, Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies., J Infect Dis, 194, 612, 10.1086/506362

Baker, 2008, CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection., AIDS, 22, 841, 10.1097/QAD.0b013e3282f7cb76

Roux, 2009, Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment., Clin Infect Dis, 49, 1433, 10.1086/630209

Leaver, 2007, The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature., AIDS Behav, 11, 85, 10.1007/s10461-007-9246-3

Aidala, 2007, Housing need, housing assistance, and connection to HIV medical care., AIDS Behav, 11, 101, 10.1007/s10461-007-9276-x

Kidder, 2007, Health status, health care use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS., Am J Public Health, 97, 2238, 10.2105/AJPH.2006.090209

Loughlin, 2004, Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users., AIDS Care, 16, 485, 10.1080/09540120410001683411

Petersen, 2007, Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis., Clin Infect Dis, 45, 908, 10.1086/521250

Royal, 2009, Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV., AIDS Care, 21, 448, 10.1080/09540120802270250

Azar, 2010, A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization., Drug Alcohol Depend, 112, 178, 10.1016/j.drugalcdep.2010.06.014

Pence, 2008, The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy., J Acquir Immune Defic Syndr, 47, 194, 10.1097/QAI.0b013e31815ace7e

Kim, 2007, Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems., AIDS Care, 19, 1039, 10.1080/09540120701294245

Baum, 2009, Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users., J Acquir Immune Defic Syndr, 50, 93, 10.1097/QAI.0b013e3181900129

Lucas, 2002, Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic., AIDS, 16, 767, 10.1097/00002030-200203290-00012

Bertholet, 2005, Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis., Arch Intern Med, 165, 986, 10.1001/archinte.165.9.986

Amato, 2008, Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence., Cochrane Database Syst Rev, 4, CD004147

del Castillo, 2008, Influence of antiretroviral treatment on quality of life in seropositive inmates., Int J STD AIDS, 19, 172, 10.1258/ijsa.2007.007093

Murri, 2003, Determinants of health-related quality of life in HIV-infected patients., AIDS Care, 15, 581, 10.1080/0954012031000134818

Mannheimer, 2005, Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence., AIDS Care, 17, 10, 10.1080/09540120412331305098

Anand, 2010, Neurocognitive Impairment and HIV risk factors: a reciprocal relationship AIDS Behav., , 14, 1213

Korthius, 2011, Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics., J Acquir Immune Defic Syndr, 56, S39, 10.1097/QAI.0b013e318209754c

Parienti, 2008, Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels., PLoS One, 3, e2783, 10.1371/journal.pone.0002783

Gardner, 2009, Antiretroviral medication adherence and the development of class-specific antiretroviral resistance., AIDS, 23, 1035, 10.1097/QAD.0b013e32832ba8ec

Lima, 2009, The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time., J Acquir Immune Defic Syndr, 50, 529, 10.1097/QAI.0b013e31819675e9

Egger, 2002, Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies., Lancet, 360, 119, 10.1016/S0140-6736(02)09411-4

Kohli, 2005, Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy., Clin Infect Dis, 41, 864, 10.1086/432883

Kavasery, 2009, Nonstructured treatment interruptions among injection drug users in Baltimore, MD., J Acquir Immune Defic Syndr, 50, 360, 10.1097/QAI.0b013e318198a800

Maisels, 2001, An investigation of why eligible patients do not receive HAART., AIDS Patient Care STDs, 15, 185, 10.1089/10872910151133701

Chander, 2006, Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy., Drugs, 66, 769, 10.2165/00003495-200666060-00004

Wong, 2004, Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients., J Gen Intern Med, 19, 366, 10.1111/j.1525-1497.2004.30429.x

Wagner, 2003, Adherence to HIV antiretrovirals among persons with serious mental illness., AIDS Patient Care STDs, 17, 179, 10.1089/108729103321619782

Mellins, 2009, Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders., AIDS Care, 21, 168, 10.1080/09540120802001705

Bruce, 2003, Editorial comment: why treat three conditions when it is one patient?, AIDS Read, 13, 378

Weiss, 2011, Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative., J Acquir Immune Defic Syndr, 56, S68, 10.1097/QAI.0b013e31820a8226

Basu, 2006, Models for integrating buprenorphine therapy into the primary HIV care setting., Clin Infect Dis, 42, 716, 10.1086/500200